title: [Lymphoproliferative disorders in kidney transplant recipients: incidence, clinical characteristics and outcome].
abstract: OBJECTIVE
  The aim of this study was to determine the epidemiological and the clinical characteristics of post-transplant lymphoproliferative disease (PTLD) and to evaluate its impact on patients' and grafts' survival.
  
  
  METHODS
  Three hundred and sixteen adult kidney recipients, transplanted between June 1986 and May 2006, were included. The incidence rates were calculated by dividing the number of different events (PTLD, death and graft-loss) by the total duration of follow-up. The survival rates and the cumulated frequency of PTLD were calculated according to the actuarial method.
  
  
  RESULTS
  Seven recipients developed PTLD during a cumulated follow-up of 2202 years. The annual incidence was of 0.32% (95% CI : 0.30-0.34). It was of 0.81% (0.70-0.92) in recipients of kidneys from deceased donors, and of 0.25% (0.23-0.27) in patients transplanted from living donors (NS). The delay after transplantation for the diagnosis of PTLD ranged from 7.4 months to 7.7 years. PTLD was a B cell lymphoma in six cases and affected extra nodal sites in most of the cases. The treatment, comprising the cessation of immunosuppressive therapy in all cases, resulted in complete remission in four patients. Three patients died, representing an annual death rate of 6.1%, versus 2.8% in patients without PTLD (NS). The annual incidence of graft loss was 6.1% versus 3.2% among patients without PTLD (NS).
  
  
  CONCLUSIONS
  PTLD was observed in 2.2% of our patients, with an annual incidence of 0.32%. It resulted in a decrease of both patients' and grafts' survivals. Preventive measures, including the improvement of the monitoring of immunosuppressive drugs and the prevention of viral infections, should be considered to reduce the risk of PTLD.
authors.affiliation: Service de médecine interne A et laboratoire de pathologie rénale (santé 02), hôpital Charles-Nicolle, boulevard du 9-Avril, 1006 BS, Tunis, Tunisie. abderrahim.ezzeddine@rns.tn
authors.forename: E
authors.initials: E
authors.lastname: Abderrahim
authors.forename: A
authors.initials: A
authors.lastname: Harzallah
authors.forename: S
authors.initials: S
authors.lastname: Barbouch
authors.forename: S
authors.initials: S
authors.lastname: Turki
authors.forename: I
authors.initials: I
authors.lastname: Helal
authors.forename: T
authors.initials: T
authors.lastname: Ben Abdallah
authors.forename: H
authors.initials: H
authors.lastname: Hedri
authors.forename: F
authors.initials: F
authors.lastname: Ben Moussa
authors.forename: R
authors.initials: R
authors.lastname: Bardi
authors.forename: K
authors.initials: K
authors.lastname: Ayed
authors.forename: H
authors.initials: H
authors.lastname: Ben Maïz
authors.forename: A
authors.initials: A
authors.lastname: Kheder
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D016030:Kidney Transplantation / Q000009:adverse effects*; D008232:Lymphoproliferative Disorders / Q000453:epidemiology* / Q000209:etiology / Q000401:mortality; D008297:Male; D011183:Postoperative Complications / Q000453:epidemiology* / Q000401:mortality; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D014416:Tunisia / Q000453:epidemiology